ReviewTherapeutic innovation & regulatory science2021
Key Steps Toward a Promotional Communications Strategy: Collaboration Best Practices for Teams Creating Promotional Materials and Regulatory Colleagues.
Review in Therapeutic innovation & regulatory science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A promotional communications strategy is considered early in prescription medical product development by commercial disciplines (e.g., commercial/marketing) and informs promotional materials to key stakeholders such as healthcare providers and patients. Health economics and outcomes research (HEOR) is a scientific discipline that is also responsible for the generation of promotional materials to other key stakeholders such as payors. The overarching promotional strategy benefits from consistent partnerships with regulatory affairs colleagues, culminating in cost savings and patient-centric promotional materials. Yet there is a paucity of published content that details effective collaboration between promotional teams and regulatory colleagues prior to medical/legal/regulatory (MLR) review. The following review aims to showcase such organizational innovation from the perspective of teams developing promotional materials (i.e., commercial and HEOR). Behind-the-scenes marketing activities are described in relation to the following key steps that build the strategy's foundation: insight gathering from key stakeholders; sub-strategy development; tactic identification; and promotional message development. Integration of regulatory colleagues with teams developing promotional materials is imperative to accomplish these key steps prior to any MLR review. Finally, four themes in best practices for collaboration with regulatory colleagues are shared from the perspective of commercial disciplines and HEOR, alongside a real-world example for each: (1) Alignment of Strategies; (2) Shared Process & Tools; (3) Creative Problem-Solving; and (4) Culture of Connecting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.